Regions :: Western Europe :: Germany
Merck KGaA increases commitment to venture capital fund for start-up biotech firms to €100 million
7:14 AM MDT | May 16, 2013 | Deepti Ramesh
Merck KGaA says it will increase its commitment to its strategic corporate venture capital fund MS Ventures to €100 million ($129 million). MS Ventures is the corporate venture capital fund of Merck Serono, the biopharmaceutical division of Merck. MS Ventures was originally established in March 2009 with a €40 million commitment to invest in emerging biotechnology companies. The new increased commitment secures a long term mandate and will allow MS Ventures to significantly expand its investment activities while still focused on Merck Serono’s...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee